| Systematic review and meta-analysis of the accuracy and applicability of blood-based multi-cancer early detection (MCED) in the general population. JH Park, Y Oh, LIY Chung, R Duan, TA Djunadi, SM Yoon, Z Shah, ... Journal of Clinical Oncology 41 (16_suppl), 3069-3069, 2023 | 4 | 2023 |
| Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments Y Oh, SM Yoon, J Lee, JH Park, S Lee, T Hong, LI Chung, S Sudhaman, ... Thoracic Cancer 15 (13), 1095-1102, 2024 | | 2024 |
| Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in non small cell lung cancer (NSCLC) in patients treated with immunotherapy M Yadav, J Lee, PH Kim, S Lee, T Um, S Lee, MJ Chuchuca, TA Djunadi, ... Cancer Research 84 (6_Supplement), 7529-7529, 2024 | | 2024 |
| AI-powered radiomics model predicts immune checkpoint inhibitor-related pneumonitis (CIP) in advanced NSCLC patients S Lee, A Hiremath, J Lee, PH Kim, K Zhang, S Lee, M Yadav, ... Cancer Research 84 (6_Supplement), 2594-2594, 2024 | | 2024 |
| Harmonization radiomics models to predict tumor response in non-small cell lung cancer (NSCLC) patients treated with immunotherapy M Yadav, J Lee, PH Kim, S Lee, T Um, S Lee, MJ Chuchuca, TA Djunadi, ... Cancer Research 84 (6_Supplement), 7530-7530, 2024 | | 2024 |
| CheckpointPx, an interpretable radiology AI tool, predicts checkpoint blockade benefit independent of PDL1 status in non-small cell lung cancers (NSCLC): A multi-institutional … A Hiremath, S Lee, J Lee, PH Kim, K Zhang, S Lee, M Yadav, ... Cancer Research 84 (6_Supplement), 912-912, 2024 | | 2024 |
| Accelerated and precise tumor segmentation in NSCLC: A comparative analysis of automated ClickSeg and manual annotation for radiomics S Lee, K Zhang, J Lee, PH Kim, A Hiremath, S Lee, M Yadav, ... Cancer Research 84 (6_Supplement), 2595-2595, 2024 | | 2024 |
| Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy TA Djunadi, Y Oh, J Lee, J Yu, LIY Chung, Y Lee, L Kim, T Hong, S Lee, ... Clinical Lung Cancer, 2024 | | 2024 |
| 1299 Radiomics features to predict tumor response and biomarker status in non-small cell lung cancer (NSCLC) patients treated with immunotherapy J Lee, MJA Chuchuca, PH Kim, T Um, M Jenkin, M Nam, LIY Chung, J Yu, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 1298 Radiomics features to predict immune checkpoint inhibitor-related pneumonitis (CIP) in NSCLC patients treated with immunotherapy J Lee, H Kim, MJA Chuchuca, T Um, M Jenkin, M Nam, LIY Chung, J Yu, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Systematic review and meta-analysis of accuracy of tumor origin detection in blood cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) assays in the general population. JH Park, Y Oh, LIY Chung, R Duan, TA Djunadi, SM Yoon, Z Shah, ... Journal of Clinical Oncology 41 (16_suppl), e15053-e15053, 2023 | | 2023 |
| Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC … J Yu, Y Velichko, H Kim, N Gennaro, M Soliman, L Kim, Y Oh, TA Djunadi, ... Journal of Clinical Oncology 41 (16_suppl), e21217-e21217, 2023 | | 2023 |
| Radiomics-based machine learning models to predict progression and biomarker status in non-small cell lung cancer (NSCLC) patients treated with immunotherapy J Yu, Y Velichko, H Kim, M Soliman, N Gennnaro, L Kim, Y Oh, ... Cancer Research 83 (7_Supplement), 5619-5619, 2023 | | 2023 |
| Systematic review and meta-analysis of the accuracy of tumor origin detection in blood-based multi-cancer early detection (MCED) in the general population Y Oh, JH Park, LIY Chung, R Duan, TA Djunadi, SM Yoon, Z Shah, ... Cancer Research 83 (7_Supplement), 784-784, 2023 | | 2023 |
| REAL-WORLD TISSUE-BASED CIRCULATING TUMOR DNA (CTDNA) MINIMAL RESIDUAL DISEASE (MRD) ASSAY PREDICTS OUTCOME IN LUNG CANCER PATIENTS WHO HAD CURATIVE TREATMENTS Y Oh, LIY Chung, S Lee, T Hong, L Kim, SM Yoon, JH Park, TA Djunadi, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 10, A15-A15, 2022 | | 2022 |
| 13 Real-world tissue-based circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay predicts outcome in lung cancer patients who had curative treatments Y Oh, LIY Chung, S Lee, T Hong, L Kim, SM Yoon, JH Park, TA Djunadi, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 1407 Understanding the definition of hyperprogressive disease (HPD) and its incidence–a new path forward TA Djunadi, Y Oh, LIY Chung, T Hong, S Lee, Z Shah, JH Park, SM Yoon, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 1413 The overall survival (OS) and progression-free survival (PFS) of hyperprogressive disease (HDP) in lung cancer patients Y Oh, TA Djunadi, LIY Chung, S Lee, T Hong, Z Shah, JH Park, SM Yoon, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 1408 Risk factors for hyperprogressive disease in lung cancer patients using two different definitions TA Djunadi, Y Oh, LIY Chung, T Hong, S Lee, Z Shah, JH Park, SM Yoon, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
